OBJECTIVE: We sought to identify effective chemotherapy regimens against uterine serous papillary adenocarcinoma (USPC). STUDY DESIGN: Six USPC, half of which overexpress HER-2/neu at 3+ level, were evaluated for growth rate and in vitro sensitivity to 14 single-agent chemotherapies and 5 combinations by ChemoFx (Precision Therapeutics Inc, Pittsburgh, PA). RESULTS: Cell lines overexpressing HER-2/neu showed higher proliferation when compared to low HER-2/neu-expressing cell lines and a lower half maximum inhibitory concentration (IC(50)) when exposed to the majority of single-agent chemotherapies. High HER-2/neu expressors were more sensitive to platinum compounds, manifesting a 5.22-fold decrease in carboplatin-IC(50) (P = .005) and a 5.37-fold decrease in cisplatin-IC(50) (P = .02). When all cell lines were analyzed as a group, chemotherapy agents tested demonstrated lower IC(50) when used in combination than as individual agents. CONCLUSION: USPC overexpressing HER-2/neu display greater in vitro sensitivity to platinum compounds when compared to low HER-2/neu expressors. Higher proliferative capability rather than increased drug resistance may be responsible for the adverse prognosis associated with HER-2/neu overexpression in USPC. Copyright (c) 2010 Mosby, Inc. All rights reserved.
OBJECTIVE: We sought to identify effective chemotherapy regimens against uterine serous papillary adenocarcinoma (USPC). STUDY DESIGN: Six USPC, half of which overexpress HER-2/neu at 3+ level, were evaluated for growth rate and in vitro sensitivity to 14 single-agent chemotherapies and 5 combinations by ChemoFx (Precision Therapeutics Inc, Pittsburgh, PA). RESULTS: Cell lines overexpressing HER-2/neu showed higher proliferation when compared to low HER-2/neu-expressing cell lines and a lower half maximum inhibitory concentration (IC(50)) when exposed to the majority of single-agent chemotherapies. High HER-2/neu expressors were more sensitive to platinum compounds, manifesting a 5.22-fold decrease in carboplatin-IC(50) (P = .005) and a 5.37-fold decrease in cisplatin-IC(50) (P = .02). When all cell lines were analyzed as a group, chemotherapy agents tested demonstrated lower IC(50) when used in combination than as individual agents. CONCLUSION: USPC overexpressing HER-2/neu display greater in vitro sensitivity to platinum compounds when compared to low HER-2/neu expressors. Higher proliferative capability rather than increased drug resistance may be responsible for the adverse prognosis associated with HER-2/neu overexpression in USPC. Copyright (c) 2010 Mosby, Inc. All rights reserved.
Authors: Alessandro D Santin; Stefania Bellone; Sue Van Stedum; Wendy Bushen; Michela Palmieri; Eric R Siegel; Luis E De Las Casas; Juan J Roman; Alexander Burnett; Sergio Pecorelli Journal: Cancer Date: 2005-10-01 Impact factor: 6.860
Authors: Teresa P Díaz-Montes; Hongxiu Ji; Ann E Smith Sehdev; Mariana L Zahurak; Robert J Kurman; Deborah K Armstrong; Robert E Bristow Journal: Gynecol Oncol Date: 2005-09-22 Impact factor: 5.482
Authors: Carl Morrison; Vanna Zanagnolo; Nilsa Ramirez; David E Cohn; Nicole Kelbick; Larry Copeland; G Larry Maxwell; Larry G Maxwell; Jeffrey M Fowler Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: H Gallion; W A Christopherson; R L Coleman; L DeMars; T Herzog; S Hosford; H Schellhas; A Wells; B-U Sevin Journal: Int J Gynecol Cancer Date: 2006 Jan-Feb Impact factor: 3.437
Authors: Alessandro D Santin; Stefania Bellone; Eric R Siegel; Michela Palmieri; Maria Thomas; Martin J Cannon; Helen H Kay; Juan J Roman; Alexander Burnett; Sergio Pecorelli Journal: Am J Obstet Gynecol Date: 2005-03 Impact factor: 8.661
Authors: Claire M Mach; Jong Kim; Benjamin Soibam; Chad J Creighton; Shannon M Hawkins; Israel Zighelboim; Paul Goodfellow; Preethi H Gunaratne; Kunle Odunsi; Philip A Salem; Matthew L Anderson Journal: Cancer Lett Date: 2013-02-26 Impact factor: 8.679
Authors: Joyce Varughese; Emiliano Cocco; Stefania Bellone; Maria de Leon; Marta Bellone; Paola Todeschini; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin Journal: Cancer Date: 2011-01-18 Impact factor: 6.860
Authors: Yang Deng; Fan Yang; Emiliano Cocco; Eric Song; Junwei Zhang; Jiajia Cui; Muneeb Mohideen; Stefania Bellone; Alessandro D Santin; W Mark Saltzman Journal: Proc Natl Acad Sci U S A Date: 2016-09-23 Impact factor: 11.205
Authors: Dana M Roque; Stefania Bellone; Diana P English; Natalia Buza; Emiliano Cocco; Sara Gasparrini; Ileana Bortolomai; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin Journal: Cancer Date: 2013-04-12 Impact factor: 6.860
Authors: E Cocco; Z Hu; C E Richter; S Bellone; F Casagrande; M Bellone; P Todeschini; G Krikun; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; N Buza; S Pecorelli; C J Lockwood; A D Santin Journal: Br J Cancer Date: 2010-08-10 Impact factor: 7.640
Authors: S Bellone; R Tassi; M Betti; D English; E Cocco; S Gasparrini; I Bortolomai; J D Black; P Todeschini; C Romani; A Ravaggi; E Bignotti; E Bandiera; L Zanotti; S Pecorelli; L Ardighieri; M Falchetti; C Donzelli; E R Siegel; M Azodi; D-A Silasi; E Ratner; P E Schwartz; T J Rutherford; A D Santin Journal: Br J Cancer Date: 2013-06-27 Impact factor: 7.640